GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Akari Therapeutics
Akari Therapeutics is a biotech company developing drugs to treat inflammatory diseases. Its stock price is highly volatile and depends on the results of clinical trials.
Share prices of companies in the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing complement inhibitors for the treatment of rare autoimmune and inflammatory diseases. We have classified it in the Pharma: Immunology category. The chart below shows how investors value companies in this complex field.
Broad Market Index - GURU.Markets
Akari Therapeutics is a biopharmaceutical company developing complement inhibitors for the treatment of rare autoimmune and inflammatory diseases. It is a component of the GURU.Markets index, and the chart below shows how its stock compares to the broader market.
Change in the price of a company, segment, and market as a whole per day
AKTX - Daily change in the company's share price Akari Therapeutics
Akari Therapeutics, Plc's daily price change reflects the extreme volatility inherent in biotech companies. This metric measures the company's sensitivity to news about clinical trials of its drugs for rare diseases.
Daily change in the price of a set of shares in a market segment - Pharma immune
Akari Therapeutics, Plc is a biotech company. This chart highlights the sector's extreme volatility. Comparison with AKTX, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Akari Therapeutics is a biotech company focused on immunology. Its shares, like many in the sector, are highly volatile and react to news about clinical trials. These science-driven movements are part of the complex and diverse landscape of the entire stock market.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Akari Therapeutics
Akari Therapeutics, Plc's year-to-date performance is a story about the development of its complement inhibitor, nomicopan. Its 12-month market cap is entirely dependent on clinical trial data. Success in treating rare inflammatory diseases could be a fundamental breakthrough for the company and confirm the potential of its core asset.
Annual dynamics of market capitalization of the market segment - Pharma immune
Akari Therapeutics, Plc. is a late-stage biotech developing drugs to treat rare immunological diseases. Its stock performance is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akari Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Akari Therapeutics
Akari Therapeutics is a clinical-stage biopharmaceutical company. Its monthly performance is entirely dependent on the results of its clinical trials. News about its lead drug, nomacopan, are binary events, causing sharp price fluctuations.
Monthly dynamics of market capitalization of the market segment - Pharma immune
Akari Therapeutics is a biotech company developing drugs to treat rare autoimmune and inflammatory diseases. Its future depends entirely on the results of clinical trials. The biotech sector's performance, as shown in the chart, is a general barometer of investor appetite for risky but potentially breakthrough scientific projects, of which Akari is one.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Akari Therapeutics, Plc. is a late-stage biopharmaceutical company developing complement inhibitors for the treatment of rare and orphan diseases. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to demonstrate how its scientific data and trial progress have driven its stock price movement independently.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Akari Therapeutics
Akari Therapeutics, a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases, is extremely volatile. Its weekly stock price is almost exclusively a direct reaction to the release of clinical trial data, which determines the market's assessment of its scientific developments.
Weekly dynamics of market capitalization of the market segment - Pharma immune
Akari Therapeutics operates in the volatile biopharmaceutical sector, where investor sentiment often influences all players. M&A news or general regulatory changes can lift or derail the entire sector. The chart will show whether AKTX is moving with the industry or whether its drug development successes are creating its own story.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Akari Therapeutics, as a biotech company, often ignores broader market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how AKTX shares can rise or fall on their own news, while the overall market moves in a different direction.
Market capitalization of the company, segment and market as a whole
AKTX - Market capitalization of the company Akari Therapeutics
Akari Therapeutics' stock chart is a volatile story of drug development for rare immune diseases. This biotech's market cap is a rollercoaster, with every peak and trough directly tied to clinical trial news. It's a classic high-risk bet on a scientific breakthrough.
AKTX - Share of the company's market capitalization Akari Therapeutics within the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its market share is based on the potential of its lead candidate, which targets the complement system. The chart shows how the market assesses its chances of success in this complex area of medicine.
Market capitalization of the market segment - Pharma immune
Akari Therapeutics develops drugs to treat rare autoimmune and inflammatory diseases. The chart below shows the market capitalization of the immunology pharmaceutical sector. This represents an industry where a breakthrough in treating a rare disease can bring enormous success.
Market capitalization of all companies included in a broad market index - GURU.Markets
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its market capitalization reflects the potential of its scientific research. The chart below shows the economic weight of companies solving orphan diseases.
Book value capitalization of the company, segment and market as a whole
AKTX - Book value capitalization of the company Akari Therapeutics
Akari Therapeutics is built on scientific capital. This biotech company's book value reflects its intellectual property in its development of nomacopan, a drug for treating rare immune diseases, and the funds it has for its clinical trials. The chart below shows how the company is using its financial resources to advance its key development.
AKTX - Share of the company's book capitalization Akari Therapeutics within the market segment - Pharma immune
Akari Therapeutics, a biopharmaceutical company, is focused on R&D. Its tangible assets are research laboratories. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for innovative companies in the research stage.
Market segment balance sheet capitalization - Pharma immune
Akari Therapeutics is a clinical-stage biopharmaceutical company. Its value lies in the potential of its drugs in development and the associated patents. A book value chart shows that its assets are almost entirely intangible, which is typical for an innovative company far from mass production.
Book value of all companies included in the broad market index - GURU.Markets
Akari Therapeutics' book value represents capital focused on rare inflammatory diseases. The company's assets consist of the development rights to its lead drug, nomicopan, and the financial resources to conduct clinical trials. The chart shows the size of its capital base, which is focused on developing a new drug for the treatment of the eyes and lungs.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Akari Therapeutics
Akari Therapeutics is a clinical-stage biopharmaceutical company. Its book value is primarily cash on hand. Its market capitalization is a pure reflection of investor confidence in the potential of its investigational drugs for treating rare immune diseases. The chart shows the volatility of these hopes.
Market to book capitalization ratio in a market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company focused on treating rare immune diseases. Its value depends almost entirely on the success of clinical trials. The chart shows how market expectations for its drugs compare to its tangible assets, which consist primarily of cash.
Market to book capitalization ratio for the market as a whole
Akari Therapeutics is a biopharmaceutical company focused on treating rare immune diseases. Its value is almost entirely determined by the potential of its research portfolio. The market values the company's hopes for breakthrough drugs. The chart clearly demonstrates the gap between its market capitalization and book value.
Debts of the company, segment and market as a whole
AKTX - Company debts Akari Therapeutics
For Akari Therapeutics, a clinical-stage biopharmaceutical company, debt is a vital resource. This chart shows how the company is raising funds to finance lengthy and expensive clinical trials of its drugs for rare immune diseases. It's an investment in science in anticipation of a breakthrough.
Market segment debts - Pharma immune
Akari Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare immune diseases. For such companies, a lack of revenue and reliance on equity capital to fund R&D are the norm. Debt is unusual at this stage. This chart reflects the company's financial health and its ability to continue research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. This chart shows its leverage. For a company in clinical development with no stable revenue, any level of debt is a significant risk that could impact its ability to finance the long road to market.
Market segment debt to market segment book capitalization - Pharma immune
Akari Therapeutics is a biopharmaceutical company focused on immune diseases. This biotech chart illustrates investors' appetite for risk and funding expensive research. It helps us understand how the company's financial position is typical for an industry where the stakes and potential rewards are extremely high.
Debt to book value of all companies in the market
Akari Therapeutics develops drugs to treat rare autoimmune and inflammatory diseases. The biotech sector often requires significant investment. A chart of the market's total debt to book value ratio helps understand how willing investors are to finance long-term and risky developments, which directly impacts the future of companies like Akari.
P/E of the company, segment and market as a whole
P/E - Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare immune and inflammatory diseases. This chart reflects investor expectations for the success of its clinical trials. Its value reflects the estimated potential market for its drugs, where the approval of even one drug could lead to a multiple increase in value.
P/E of the market segment - Pharma immune
Akari Therapeutics is a biotech company. This chart shows the average P/E ratio for the industry, which is an indicator of overall risk appetite. Comparing the company's P/E to this ratio allows us to understand how much higher or lower the market believes the success rate of its specific immune-disease treatments is.
P/E of the market as a whole
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare immune and inflammatory diseases. Its value depends on the success of clinical trials. This chart shows the overall risk appetite in biotech. It helps us understand whether Akari's valuation is a response to specific scientific data or simply follows the general ups and downs of the speculative biotech sector.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs for the treatment of rare autoimmune and inflammatory diseases. The chart reflects speculative revenue expectations, which are entirely dependent on the success of clinical trials. Investors are betting on the scientific potential of its lead drug candidate.
%20P%2FE%20Akari%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Akari-Therapeutics&v=1772513747333 "Chart of the company's future (projected) P/E Akari Therapeutics")
Future (projected) P/E of the market segment - Pharma immune
Akari Therapeutics develops drugs to treat rare autoimmune and inflammatory diseases by targeting the complement system. This chart shows its expected future profitability, allowing us to assess how highly the market values its scientific approach to developing targeted therapies for orphan diseases.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-immune&v=1772513747363 "Future (projected) P/E graph of the market segment - Pharma immune")
Future (projected) P/E of the market as a whole
Akari Therapeutics is a clinical-stage biotech company developing drugs to treat rare immune diseases. Its value is based on the pure expectation of the future success of its drug candidates. It is completely uncorrelated with general market forecasts and depends solely on scientific data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513747366 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Being in the clinical stage, it incurs significant research expenses. This chart reflects its investment in clinical trials, which are key to future commercialization and potential profit from innovative drugs.
Profit of companies in the market segment - Pharma immune
Akari Therapeutics is a clinical-stage biopharmaceutical company developing drugs for the treatment of rare autoimmune and inflammatory diseases. This chart shows the overall profitability of its segment. Like many biotechs in the R&D phase, Akari currently contributes negatively to overall profit. However, the success of its developments could lead to a breakthrough and become a driver of future growth for the entire industry.
Overall market profit
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its value and prospects depend solely on the results of clinical trials. The presented gross profitability chart shows the dynamics of a traditional economy, while Akari is working to create value in the high-tech biotech space.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases. For a clinical-stage company, this chart reflects potential future revenue rather than current profit. It demonstrates analysts' confidence in the company's scientific platform and the likelihood of successful clinical trials, which are key factors for its future.
%20profit%20of%20the%20company%20Akari%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Akari-Therapeutics&v=1772513747438 "Graph of future (projected) profit of the company Akari Therapeutics")
Future (predicted) profit of companies in the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing inhibitors for the treatment of autoimmune and inflammatory diseases. This chart shows profitability forecasts for the immunology pharmaceutical segment. It reflects the overall market optimism or pessimism regarding the development of new treatments, providing context for Akari's clinical trials.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-immune&v=1772513747477 "Graph of future (predicted) profits of companies in a market segment - Pharma immune")
Future (predicted) profit of the market as a whole
Akari Therapeutics is a biotech company developing drugs to treat rare immune diseases. While their developments are not dependent on economic cycles, biotech financing is quite robust. During periods of expected profit growth, investors are more willing to invest in riskier projects. The chart below illustrates this investment climate.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513747512 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing treatments for rare immune diseases. While in the clinical stage, it may not have stable revenue. P/S will be a key metric after the product's launch to assess how the market will perceive its innovative therapy and its commercial potential.
P/S market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing treatments for rare autoimmune and autoinflammatory diseases. Being in the clinical stage, its valuation is based on future potential. This chart shows how high investor expectations for its developments are compared to other immunology biotech companies.
P/S of the market as a whole
Akari Therapeutics is a biotech company developing drugs to treat rare immune and inflammatory diseases. It currently has no revenue, and its valuation reflects the potential of its research and development pipeline. This chart, based on actual revenue, clearly demonstrates that Akari's valuation is a bet on future success in clinical trials.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its valuation is based almost entirely on future potential. This chart reflects investor expectations for future revenue from the commercialization of its developments, assuming they successfully complete clinical trials and receive approval.
%20P%2FS%20Akari%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Akari-Therapeutics&v=1772513747606 "The graph of the company's future (projected) P/S Akari Therapeutics")
Future (projected) P/S of the market segment - Pharma immune
Akari Therapeutics, Plc., is a clinical-stage biopharmaceutical company developing complement inhibitors for the treatment of rare autoimmune and inflammatory diseases. This chart shows how the market assesses the future commercial potential of its drug candidates. It compares the company to other immunology companies, reflecting confidence in its scientific approach.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20immune&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-immune&v=1772513747634 "Future (projected) P/S market segment graph - Pharma immune")
Future (projected) P/S of the market as a whole
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its valuation is a bet on the success of clinical trials. This chart shows revenue expectations for the entire market, and Akari demonstrates how the high-risk biotech sector, brimming with hopes for breakthroughs, influences long-term investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513747668 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Akari Therapeutics
Akari Therapeutics is a clinical-stage biopharmaceutical company focused on treating rare autoimmune and inflammatory diseases. Because its drugs are still in development, revenue in this chart is typically absent or consists of licensing fees rather than final product sales.
Sales of companies in the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing drugs to treat autoimmune and inflammatory diseases. Currently, its revenue, if any, is derived from licensing agreements. This chart shows financial flows from partners that validate the potential of its research.
Overall market sales
Akari Therapeutics is a biopharmaceutical company developing treatments for rare autoimmune and inflammatory diseases. Its success depends entirely on the results of clinical trials. This market performance chart is not directly related to Akari, whose value is determined by scientific data and the potential of its drugs, not economic cycles.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs for the treatment of rare autoimmune and inflammatory diseases. Its revenue forecast depends on the success of clinical trials and the future commercial potential of its candidates. This chart reflects analysts' speculative expectations for its research pipeline.
%20sales%20of%20the%20company%20Akari%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Akari-Therapeutics&v=1772513747759 "Schedule of future (projected) sales of the company Akari Therapeutics")
Future (projected) sales of companies in the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing treatments for rare autoimmune and inflammatory diseases. This chart shows projected revenue for the entire immunology segment. It provides insight into the size and growth analysts expect of this complex market, which is critical to the commercial potential of Akari's developments.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-immune&v=1772513747785 "Schedule of future (projected) sales of companies in the market segment - Pharma immune")
Future (projected) sales of the market as a whole
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. Its success depends on the results of clinical trials. However, the overall market environment, shown in the chart, influences investor sentiment, which affects the company's ability to raise capital to fund expensive research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513747794 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company developing drugs to treat rare autoimmune and inflammatory diseases. This chart reflects its current focus on research. It doesn't show profits, but rather the effectiveness of managing capital invested in clinical trials, the success of which determines the company's entire future value.
Market segment marginality - Pharma immune
Akari Therapeutics is a biopharmaceutical company developing inhibitors for the treatment of rare autoimmune and inflammatory diseases. The chart below shows the average profitability in the immunology sector. It provides context for assessing the potential profitability of Akari's drugs, should they be successful, by comparing them to the overall profitability in this niche.
Market marginality as a whole
Akari Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare immune diseases. Its value reflects the hope for future research success. This chart, showing average market profitability, bears no relation to the binary logic of biotech, where a single successful drug can create enormous value.
Employees in the company, segment and market as a whole
Number of employees in the company Akari Therapeutics
Akari Therapeutics is a clinical-stage biopharmaceutical company developing drugs to treat rare immune diseases. Its small but highly qualified team consists of scientists and clinicians. This graph shows the size of the team, which leads complex scientific developments where success depends on expertise, not headcount.
Share of the company's employees Akari Therapeutics within the market segment - Pharma immune
Akari Therapeutics is a biopharmaceutical company focused on treating rare autoimmune and inflammatory diseases. This chart reflects the concentration of scientific expertise. It shows the proportion of immunologists and researchers working on a specific complement inhibitor, C5, that Akari brings together to create a therapy for patients with limited treatment options.
Number of employees in the market segment - Pharma immune
Akari Therapeutics develops drugs to treat rare autoimmune and autoinflammatory diseases. This chart shows employment in the immunology sector. The rapid growth in the number of specialists in this field indicates significant progress in understanding the immune system and developing targeted therapies, a key area of Akari's research.
Number of employees in the market as a whole
Akari Therapeutics is a biopharmaceutical company focused on treating rare immunological diseases. Growth in biotech requires the recruitment of highly skilled professionals, which impacts the labor market. This chart shows overall employment, where innovative companies like Akari are creating new jobs in science-intensive fields.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Akari Therapeutics (AKTX)
Akari Therapeutics, a biopharmaceutical company in the research stage, is valued based on investor expectations. This chart shows the enormous value the market places on the research potential per employee. This is a pure valuation of intellectual capital and future patents, not current sales or assets.
%20of%20the%20company%20Akari%20Therapeutics%20(AKTX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Akari-Therapeutics-AKTX&v=1772513747973 "Chart of market capitalization per employee (in thousands of dollars) of the company Akari Therapeutics (AKTX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma immune
Akari Therapeutics is a biotech company whose value depends on the success of clinical trials, not on the number of employees. Its market capitalization per employee can be very high, reflecting investors' faith in the scientific potential of its developments. Comparisons with the sector help assess how promising the market perceives its drug portfolio.
%20by%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-immune&v=1772513748004 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma immune")
Market capitalization per employee (in thousands of dollars) for the overall market
Akari Therapeutics is a biopharmaceutical company developing drugs to treat immune-related diseases. Its value is entirely dependent on the success of clinical trials. This chart illustrates investor expectations, with a high valuation per employee reflecting confidence in the team's scientific potential and its ability to create a breakthrough treatment.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513748024 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Akari Therapeutics (AKTX)
Akari is a clinical-stage biotech company specializing in the treatment of inflammatory and autoimmune diseases. The company has no commercial products; its core business is R&D. This graph, in negative territory, shows how much investor capital is "burned" per scientist in the drug development process.
%20Chart%20Akari%20Therapeutics%20(AKTX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Akari-Therapeutics-AKTX&v=1772513748036 "Company Profit Per Employee (in thousands of dollars) Chart Akari Therapeutics (AKTX)")
Profit per employee (in thousands of dollars) in the market segment - Pharma immune
Akari Therapeutics develops innovative treatments for rare autoimmune and inflammatory diseases. For a research-stage biotech company, this graph illustrates the potential for monetizing intellectual property. It reflects the ability of a small but highly skilled team of scientists to create therapies with enormous commercial value in the future.
%20in%20the%20market%20segment%20-%20Pharma%20immune&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-immune&v=1772513748076 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma immune")
Profit per employee (in thousands of dollars) for the market as a whole
Akari Therapeutics is a biopharmaceutical company developing treatments for autoimmune and inflammatory diseases. At this stage of the company's development, this metric is likely to be negative. It reflects not current profitability, but rather the investment (expenses) in R&D and clinical trials per highly qualified scientist.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513748107 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Akari Therapeutics (AKTX)
Akari Therapeutics is a clinical-stage biopharmaceutical company. This chart doesn't reflect commercial activity, as revenue is virtually nonexistent. It illustrates the intensive research phase. If its drugs are successful, this figure could grow exponentially, demonstrating the enormous financial return on intellectual property.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Akari-Therapeutics-AKTX&v=1772513748129 "Sales chart per company employee Akari Therapeutics (AKTX)")
Sales per employee in the market segment - Pharma immune
Akari Therapeutics (AKTX) is a clinical-stage biopharmaceutical company specializing in the treatment of rare immune and inflammatory diseases. This chart shows the average revenue per employee in the pharmaceutical segment. For Akari, which is focused on R&D, this figure is low. Comparison with the benchmark highlights their stage of development, where value is created through research, not current sales.
Sales per employee for the market as a whole
Akari Therapeutics is a clinical-stage biotech company. Like other R&D companies, Akari has virtually no revenue and a staff of highly paid scientists. This metric is currently close to zero and reflects only expenses. Investors are monitoring clinical data in anticipation of approval, which could further increase this figure.
Short shares by company, segment and market as a whole
Shares shorted by company Akari Therapeutics (AKTX)
Akari Therapeutics is a clinical-stage biotech whose value is entirely dependent on the success of their experimental drug (Nomacopan) for treating inflammatory diseases. This chart shows the number of investors betting directly on the drug's failure. "Bears" expect the clinical trials to fail, and the company to run out of cash.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Akari-Therapeutics-AKTX&v=1772513748250 "Short Shares Chart for the Company Akari Therapeutics (AKTX)")
Shares shorted by market segment - Pharma immune
Akari Therapeutics is a clinical-stage biotech developing drugs to treat autoimmune diseases. Its future depends on the success of its trials. This chart shows pessimism across the immunology sector. The rise in short positions across the industry is a risk-off signal. Investors are hesitant about quick success, fearing trial failures or tightening regulations, which is weighing on the valuations of all companies in this field.
Shares shorted by the overall market
Akari Therapeutics is a clinical-stage biotech company targeting rare inflammatory diseases. Like many in the sector, their valuation reflects the hope for a future drug. This chart reflects the general fear. When investors are scared, they are unwilling to pay for expensive R&D. They are selling off AKTX shares, fearing the company will run out of cash before it receives FDA approval.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Akari Therapeutics (AKTX)
Akari Therapeutics (AKTX) is a biotech company focused on treating rare inflammatory and autoimmune diseases. Like many biotechs, the stock is volatile on news. This oscillator measures the strength of these movements. Zones above 70 and below 30 indicate when investor enthusiasm or disappointment is peaking, indicating a potential reversal.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Akari-Therapeutics-AKTX&v=1772513748323 "RSI 14 indicator chart for the company's stock Akari Therapeutics (AKTX)")
RSI 14 Market Segment - Pharma immune
Akari (AKTX) is a biotech company specializing in the treatment of rare immune and inflammatory diseases. Their key drug targets the complement system. This chart tracks overall sentiment in the Pharma/Immunology sector. It helps investors understand whether AKTX's performance reflects their trials or whether the entire biotech sector is overheated or oversold.
RSI 14 for the overall market
Akari Therapeutics (AKTX) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast AKTX (Akari Therapeutics)
Akari (AKTX) is a biopharmaceutical company developing Nomacopan, a C5 and LTB4 inhibitor for the treatment of severe autoimmune and inflammatory diseases. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-AKTX-Akari-Therapeutics&v=1772513748375 "A chart showing analyst consensus forecasts for the expected stock price. AKTX (Akari Therapeutics)")
The difference between the consensus estimate and the actual stock price AKTX (Akari Therapeutics)
Akari Therapeutics is a biotech company developing C5 inhibitors for the treatment of rare autoimmune and inflammatory diseases. This chart measures the gap between the current share price and the consensus target price. It shows the potential analysts see in their R&D portfolio and scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-AKTX-Akari-Therapeutics&v=1772513748439 "A chart showing the difference between the consensus forecast and the actual stock price. AKTX (Akari Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Pharma immune
Akari Therapeutics (AKTX) is a biotech company developing a complement inhibitor (Nomacopan) for the treatment of severe, rare autoimmune and inflammatory diseases. This chart shows analysts' overall expectations for the immunopharma sector. It reflects whether experts believe R&D success in this complex field is possible.
Analysts' consensus forecast for the overall market share price
Akari Therapeutics (AKTX) is a clinical-stage biopharmaceutical company focused on treating rare immunological diseases. This chart shows the overall market risk appetite and serves as an indicator of the open or closed funding window for speculative biotechs seeking capital.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Akari Therapeutics
Akari Therapeutics is a clinical-stage biotech focused on the complement system (a key component of immunity). Their R&D platform aims to pacify this system to treat rare inflammatory diseases (eye, kidney). This chart is a pure indicator of their R&D confidence. It doesn't reflect revenue, but rather a speculative estimate of their scientific progress and clinical trial data.
AKIMA Market Segment Index - Pharma immune
Akari Therapeutics (AKTX) is a biopharmaceutical company developing complement inhibitors (Nomirsatab) for the treatment of rare autoimmune and inflammatory eye and blood diseases. The chart shows the segment average index, helping investors assess how Akari's risks and potential in the rare disease niche compare to the sector average.
The AKIM Index for the overall market
Akari Therapeutics is a biopharmaceutical company developing complement and leukotriene inhibitors for the treatment of autoimmune and inflammatory diseases. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific story compares to overall economic trends.
